Issue 50, 2014 - Huperzine A synthesis process

A few days ago, the new chemical synthesis process of Huperzine A developed by Handan Wenkang Pharmaceutical Intermediates R&D Co.
, Ltd.
passed the scientific and technological achievements appraisal
organized by the China Petroleum and Chemical Industry Federation.
Appraisal experts believe that the new chemical process of Huperzine A developed by this project provides a technical way for large-scale production for the treatment of Alzheimer's disease, and the overall technology of the new process has reached the international leading level
.

Medical studies have proved that alkaloids such as Huperzine A extracted from Huperzine can be used to treat senile dementia
.
However, at present, the wild snake-footed lycophyllum is nearly extinct, and it is difficult to cultivate it on a large scale, and the sustainable use of snake-footed lycophyllum resources is on the verge of depletion
.
More than 20 foreign research institutions have carried out technical research on artificial chemical synthesis to replace Huperzine A APIs extracted from plants, but no breakthrough has been made
.

After unremitting efforts, Handan Wenkang Pharmaceutical Intermediate R&D Co.
, Ltd.
finally broke through the artificial synthesis technology
of Huperzine A.
The team built a 100 kg pilot plant for the chemical synthesis of Huperzine A for the first time in the world, with mature technology, stable operation, and a greater reduction in production cost than the traditional natural extraction cost, which fundamentally solved the resource depletion problem
faced by plant extraction Huperzine A raw materials.
It is estimated that in 2015, the annual output of Huperzine A of Wenkang Company will reach 200 kg, accounting for more than 60% of the global market demand, and the output value can reach 400 million yuan
.

(Body)